{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T08:15:11Z","timestamp":1789978511492,"version":"4.0.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001677","name":"INSERM","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CNRS"},{"DOI":"10.13039\/501100004431","name":"Fondation de France","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004431","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.phrs.2016.08.027","type":"journal-article","created":{"date-parts":[[2016,9,4]],"date-time":"2016-09-04T09:31:55Z","timestamp":1472981515000},"page":"257-264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"PA","title":["Terlipressin, a vasoactive prodrug recommended in hepatorenal syndrome, is an agonist of human V1, V2 and V1B receptors: Implications for its safety profile"],"prefix":"10.1016","volume":"113","author":[{"given":"Pascal H.","family":"Colson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Virsolvy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Gaudard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azzouz","family":"Charrabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5106-8801","authenticated-orcid":false,"given":"Maith\u00e9","family":"Corbani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime J.","family":"Mani\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Guillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2016.08.027_bib0005","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0168-8278(00)80158-0","article-title":"Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome","volume":"33","author":"Uriz","year":"2000","journal-title":"J. Hepatol."},{"key":"10.1016\/j.phrs.2016.08.027_bib0010","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/hep.23286","article-title":"Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome","volume":"51","author":"Gluud","year":"2010","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.phrs.2016.08.027_bib0015","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1677\/joe.0.0850237","article-title":"Conversion of triglycylvasopressin to lysine-vasopressin in man","volume":"85","author":"Forsling","year":"1980","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.phrs.2016.08.027_bib0020","first-page":"307","article-title":"Pharmacokinetics of terlipressin after single i.v. doses to healthy volunteers","volume":"16","author":"Nilsson","year":"1990","journal-title":"Drugs Exp. Clin. Res."},{"key":"10.1016\/j.phrs.2016.08.027_bib0025","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0168-8278(00)80392-X","article-title":"Terlipressin is more effective in decreasing variceal pressure than portal pressure in cirrhotic patients","volume":"32","author":"Romero","year":"2000","journal-title":"J. Hepatol."},{"key":"10.1016\/j.phrs.2016.08.027_bib0030","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1053\/gast.2002.32364","article-title":"Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study","volume":"122","author":"Moreau","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2016.08.027_bib0035","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jhep.2011.11.019","article-title":"Short course adjuvant terlipressin in acute variceal bleeding: a randomized double blind dummy controlled trial","volume":"56","author":"Azam","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.phrs.2016.08.027_bib0040","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jhep.2012.01.012","article-title":"Noradrenaline vs terlipressin in the treatment of hepatorenal syndrome: a randomized study","volume":"56","author":"Singh","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.phrs.2016.08.027_bib0045","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jhep.2010.05.004","article-title":"EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis","volume":"53","author":"European Association for the Study of the Liver","year":"2010","journal-title":"J. Hepatol."},{"key":"10.1016\/j.phrs.2016.08.027_bib0050","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jhep.2013.12.032","article-title":"Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis","volume":"60","author":"Rodr\u00edguez","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.phrs.2016.08.027_bib0055","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/sj.bjp.0701397","article-title":"Potentiation by vasopressin of adrenergic vasoconstriction in the rat isolated mesenteric artery","volume":"122","author":"Noguera","year":"1997","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2016.08.027_bib0060","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1097\/00003246-200109000-00017","article-title":"Hemodynamic effects of terlipressin (a synthetic analog of vasopressin) in healthy and endotoxemic sheep","volume":"29","author":"Scharte","year":"2001","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.phrs.2016.08.027_bib0065","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1097\/CCM.0b013e31819b8199","article-title":"Terlipressin, a provasopressin drug exhibits direct vasoconstrictor properties: consequences on heart perfusion and performance","volume":"37","author":"Ryckwaert","year":"2009","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.phrs.2016.08.027_bib0070","doi-asserted-by":"crossref","first-page":"511","DOI":"10.5527\/wjn.v4.i5.511","article-title":"Hepatorenal syndrome: update on diagnosis and treatment","volume":"4","author":"Baraldi","year":"2015","journal-title":"World J. Nephrol."},{"key":"10.1016\/j.phrs.2016.08.027_bib0075","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1161\/01.res.0000435853.85322.af","article-title":"A novel tetrodotoxin-sensitive Na+ current in cultured human coronary myocytes","volume":"80","author":"Quignard","year":"1997","journal-title":"Circ. Res."},{"key":"10.1016\/j.phrs.2016.08.027_bib0080","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1074\/mcp.M500040-MCP200","article-title":"Difference in mass analysis using labeled lysines (DIMAL-K): a new, efficient proteomic quantification method applied to the analysis of astrocytic secretomes","volume":"4","author":"Delcourt","year":"2005","journal-title":"Mol. Cell Proteomics"},{"key":"10.1016\/j.phrs.2016.08.027_bib0085","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1210\/en.2002-220363","article-title":"[1-deamino-4-cyclohexylalanine] arginine vasopressin: a potent and specific agonist for vasopressin V1b receptors","volume":"143","author":"Derick","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.phrs.2016.08.027_bib0090","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1210\/me.2011-1202","article-title":"V1b and CRHR1 receptor heterodimerization mediates synergistic biological actions of vasopressin and CRH","volume":"26","author":"Murat","year":"2012","journal-title":"Mol. Endocrinol. (Baltimore, Md.)"},{"key":"10.1016\/j.phrs.2016.08.027_bib0095","doi-asserted-by":"crossref","first-page":"17969","DOI":"10.1038\/srep17969","article-title":"Antagonism of Nav channels and \u03b11-adrenergic receptors contributes to vascular smooth muscle effects of ranolazine","volume":"5","author":"Virsolvy","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2016.08.027_bib0100","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1358\/dnp.1999.12.5.863621","article-title":"Molecular pharmacology of AVP and OT receptors and therapeutic potential","volume":"12","author":"Barberis","year":"1999","journal-title":"Drug News Perspect."},{"key":"10.1016\/j.phrs.2016.08.027_bib0105","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/bph.12249","article-title":"Pharmacological characterization of FE 201874, the first selective high affinity rat V1A vasopressin receptor agonist","volume":"170","author":"Marir","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2016.08.027_bib0110","first-page":"190","article-title":"Position 4 analogues of [deamino-Cys(1)] arginine vasopressin exhibit striking species differences for human and rat V(2)\/V(1b) receptor selectivity","volume":"12","author":"Guillon","year":"2006","journal-title":"J. Pept. Sci. Off. Publ. Eur. Pept. Soc."},{"key":"10.1016\/j.phrs.2016.08.027_bib0115","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0014-5793(85)80260-X","article-title":"Vasopressin inhibits cyclic AMP accumulation and adenylate cyclase activity in cerebral preparations","volume":"181","author":"Newman","year":"1985","journal-title":"FEBS Lett."},{"key":"10.1016\/j.phrs.2016.08.027_bib0120","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/00000539-200107000-00012","article-title":"Terlipressin for treating intraoperative hypotension: can it unmask myocardial ischemia?","volume":"93","author":"Medel","year":"2001","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.phrs.2016.08.027_bib0125","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/hep.28396","article-title":"Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: a randomized controlled study","volume":"63","author":"Cavallin","year":"2016","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.phrs.2016.08.027_bib0130","doi-asserted-by":"crossref","first-page":"R130","DOI":"10.1186\/cc7990","article-title":"Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study","volume":"13","author":"Morelli","year":"2009","journal-title":"Crit. Care Lond. Engl."},{"key":"10.1016\/j.phrs.2016.08.027_bib0135","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jss.2015.02.022","article-title":"Beneficial and side effects of arginine vasopressin and terlipressin for septic shock","volume":"195","author":"Xiao","year":"2015","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.phrs.2016.08.027_bib0140","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1002\/hep.23893","article-title":"Hyponatremia in patients treated with terlipressin for severe gastrointestinal bleeding due to portal hypertension","volume":"52","author":"Sol\u00e0","year":"2010","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.phrs.2016.08.027_bib0145","doi-asserted-by":"crossref","first-page":"F1295","DOI":"10.1152\/ajprenal.90407.2008","article-title":"Effects of terlipressin on the aquaretic system: evidence of antidiuretic effects","volume":"295","author":"Krag","year":"2008","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.phrs.2016.08.027_bib0150","first-page":"171","article-title":"Vasopressin antagonists allow demonstration of a novel type of vasopressin receptor in the rat adenohypophysis","volume":"30","author":"Jard","year":"1986","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.phrs.2016.08.027_bib0155","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1113\/jphysiol.2013.267609","article-title":"Glucocorticoids and renal Na+ transport: implications for hypertension and salt sensitivity","volume":"592","author":"Hunter","year":"2014","journal-title":"J. Physiol."},{"key":"10.1016\/j.phrs.2016.08.027_bib0160","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/hep.22293","article-title":"Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial","volume":"48","author":"Gin\u00e8s","year":"2008","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.phrs.2016.08.027_bib0165","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/hep.21101","article-title":"Adrenal insufficiency in patients with cirrhosis, severe sepsis and septic shock","volume":"43","author":"Tsai","year":"2006","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.phrs.2016.08.027_bib0170","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1002\/hep.21901","article-title":"Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome","volume":"46","author":"Krag","year":"2007","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.phrs.2016.08.027_bib0175","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1053\/j.gastro.2016.02.026","article-title":"Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1","volume":"150","author":"Boyer","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2016.08.027_bib0180","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/CCM.0000000000001380","article-title":"A selective V1A receptor agonist, selepressin, is superior to arginine vasopressin and to norepinephrine in ovine septic shock","volume":"44","author":"He","year":"2016","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.phrs.2016.08.027_bib0185","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/hep.27709","article-title":"Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial","volume":"62","author":"Cavallin","year":"2015","journal-title":"Hepatol Baltim Md"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661816304741?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661816304741?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T01:55:38Z","timestamp":1568339738000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661816304741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":37,"alternative-id":["S1043661816304741"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2016.08.027","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Terlipressin, a vasoactive prodrug recommended in hepatorenal syndrome, is an agonist of human V1, V2 and V1B receptors: Implications for its safety profile","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2016.08.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}